Amos J. de Jong

Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective

Amos J. de Jong, Tessa I. van Rijssel, Mira G. P. Zuidgeest et al. · Clinical Pharmacology & Therapeutics · 2022 · 114 citations · Full text

Law, Health Law, Clinical Research Regulation +15

Ethics review of decentralized clinical trials (DCTs): Results of a mock ethics review

Tessa I. van Rijssel, Amos J. de Jong, Yared Santa‐Ana‐Téllez et al. · Drug Discovery Today · 2022 · 36 citations · Full text

Public Health, Health Law, Bioethics +15

Predictive Value of Precision-Cut Kidney Slices as an Ex Vivo Screening Platform for Therapeutics in Human Renal Fibrosis

Emilia Bigaeva, Nataly Puerta Cavanzo, Elisabeth G. D. Stribos et al. · Pharmaceutics · 2020 · 27 citations · Full text

Medicine, Nephrology, Pharmacology +16

COVID‐19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union

Amos J. de Jong, Yared Santa‐Ana‐Téllez, Ghislaine J. M. W. van Thiel et al. · Clinical Pharmacology & Therapeutics · 2021 · 22 citations · Full text

Pharmacy, Infectious Disease Control, Pharmaceutical Policy +15

Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019–2020? A cross-sectional study in ClinicalTrials.gov

Amos J. de Jong, Renske J. Grupstra, Yared Santa‐Ana‐Téllez et al. · BMJ Open · 2022 · 21 citations · Full text

Pharmacy, Pharmaceutical Policy, Clinical Data Management +15